E76.29
Other mucopolysaccharidoses
Clinical Classification Guidelines
Inclusion Terms
- beta-Glucuronidase deficiency
- Maroteaux-Lamy (mild) (severe) syndrome
- Mucopolysaccharidosis, types VI, VII
Medical Intelligence & Overview
Other mucopolysaccharidoses (ICD-10 Code E76.29) refer to a group of rare genetic disorders caused by deficiencies in specific enzymes needed to break down complex sugars called mucopolysaccharides. When these enzymes are lacking or not functioning properly, mucopolysaccharides accumulate in the body's tissues and organs, leading to various health problems. This condition encompasses several types, including Maroteaux-Lamy syndrome and other forms of mucopolysaccharidosis types VI and VII, with varying severity.
Causes & Symptoms
Clinical Causes: Genetic mutations inherited from parents Deficiency in specific enzymes such as beta-glucuronidase Autosomal recessive inheritance pattern in most cases No prevention but early diagnosis can help manage symptoms
Key Symptoms: Coarse facial features Hearing loss Bone deformities and joint stiffness Enlarged spleen and liver Corneal clouding impairing vision Short stature Cardiac complications Delayed growth and developmental milestones Respiratory issues
Diagnostic & Treatment
Diagnosis Path: Diagnosis involves a combination of clinical evaluation and laboratory tests. These may include measuring enzyme activity levels in blood or urine samples and genetic testing to identify specific mutations. Imaging studies, such as X-rays, can reveal skeletal abnormalities typical of mucopolysaccharidoses. Early diagnosis is essential for managing the disease effectively.
Treatment Protocols: While there is no cure for other mucopolysaccharidoses, treatments aim to manage symptoms and improve quality of life. Enzyme replacement therapy (ERT) can help reduce the accumulation of mucopolysaccharides. Supportive therapies include physical therapy for mobility, surgical interventions for structural issues, and management of cardiac or respiratory problems. Regular follow-up with healthcare providers is crucial for monitoring disease progression.
Clinical Advice & FAQs
Billing Guidance
Is E76.29 a billable ICD-10 code?
Yes, E76.29 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report E76.29?
Clinical documentation must specify the nature of Other mucopolysaccharidoses and any associated comorbidities for accurate reporting.
Cite this Clinical Reference